New Zealand markets closed

ResMed Inc. (RMD)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
197.66+0.07 (+0.04%)
At close: 04:00PM EDT
197.66 0.00 (0.00%)
After hours: 04:28PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close197.59
Open199.74
Bid197.08 x 800
Ask203.00 x 1000
Day's range193.65 - 202.42
52-week range189.40 - 301.34
Volume434,399
Avg. volume571,853
Market cap28.915B
Beta (5Y monthly)0.45
PE ratio (TTM)37.30
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.68 (0.85%)
Ex-dividend date11 May 2022
1y target estN/A
  • GlobeNewswire

    Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study

    2–3 hours of nightly PAP use shows health benefits at 3 months, 1 year, and 2 yearsHealth benefits significantly increase by use hour/night, up to 7 hours SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Sleep apnea sufferers can gain health benefits from PAP (positive airway pressure) treatment in as little as two hours per night, according to a study led by ResMed (NYSE: RMD, ASX: RMD) and presented at the American Thoracic Society’s annual International Conference. The retrospective, observati

  • GlobeNewswire

    ResMed Announces Leadership Change

    SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced that Jim Hollingshead, President, Sleep and Respiratory Care, has informed ResMed that he has accepted a new position and is leaving the company, effective immediately. Rob Douglas, President and Chief Operating Officer, has been appointed interim President, Sleep and Respiratory Care. “I’d like to thank Jim for his 12 years of service and valuable contributions to ResMed,” said Mick Farrell, ResMed CEO. “Ji

  • GlobeNewswire

    ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022

    Year-over-year revenue grows 12%, operating profit up 5%, non-GAAP operating profit up 5% Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2022. Third Quarter 2022 HighlightsAll comparisons are to the prior year period Revenue increased by 12% to $864.5 million; up 14% on a constant currency basis